- Home
- GENK vs CMMB Comparison
GENK vs CMMB Comparison
Compare GENK & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- CMMB
- Stock Information
- Founded
- GENK 2011
- CMMB 2004
- Country
- GENK United States
- CMMB Israel
- Employees
- GENK N/A
- CMMB 20
- Industry
- GENK Restaurants
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- CMMB Health Care
- Exchange
- GENK Nasdaq
- CMMB Nasdaq
- Market Cap
- GENK 36.5M
- CMMB 32.2M
- IPO Year
- GENK 2023
- CMMB N/A
- Fundamental
- Price
- GENK $5.51
- CMMB $1.71
- Analyst Decision
- GENK Strong Buy
- CMMB Strong Buy
- Analyst Count
- GENK 3
- CMMB 2
- Target Price
- GENK $13.17
- CMMB $9.00
- AVG Volume (30 Days)
- GENK 63.0K
- CMMB 830.9K
- Earning Date
- GENK 03-05-2025
- CMMB 03-06-2025
- Dividend Yield
- GENK N/A
- CMMB N/A
- EPS Growth
- GENK 483.78
- CMMB N/A
- EPS
- GENK 0.17
- CMMB N/A
- Revenue
- GENK $198,834,000.00
- CMMB N/A
- Revenue This Year
- GENK $14.66
- CMMB N/A
- Revenue Next Year
- GENK $21.47
- CMMB N/A
- P/E Ratio
- GENK $33.95
- CMMB N/A
- Revenue Growth
- GENK 12.50
- CMMB N/A
- 52 Week Low
- GENK $5.26
- CMMB $0.58
- 52 Week High
- GENK $14.46
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- GENK 31.30
- CMMB 32.89
- Support Level
- GENK $5.26
- CMMB $1.66
- Resistance Level
- GENK $5.73
- CMMB $2.06
- Average True Range (ATR)
- GENK 0.35
- CMMB 0.16
- MACD
- GENK 0.01
- CMMB -0.04
- Stochastic Oscillator
- GENK 18.52
- CMMB 9.43
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.